ArticleESMO gastrointestinal oncology2025
Durvalumab plus gemcitabine-cisplatin versus S-1 plus gemcitabine-cisplatin in advanced biliary tract cancer: a comparative study.
T Satake et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.